Incyte (NASDAQ:INCY) will be posting its quarterly earnings results before the market opens on Thursday, February 15th. Analysts expect Incyte to post earnings of $0.01 per share for the quarter.
Shares of Incyte (NASDAQ INCY) opened at $86.34 on Thursday. Incyte has a 12-month low of $84.21 and a 12-month high of $153.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81. The company has a market cap of $18,220.00, a PE ratio of -107.93 and a beta of 0.59.
Several equities research analysts have recently commented on the stock. Oppenheimer reaffirmed a “hold” rating and issued a $110.00 target price (down from $120.00) on shares of Incyte in a research report on Monday, January 22nd. Raymond James Financial reaffirmed a “buy” rating on shares of Incyte in a research report on Tuesday, December 12th. BidaskClub raised shares of Incyte from a “strong sell” rating to a “sell” rating in a research report on Friday, January 26th. Zacks Investment Research cut shares of Incyte from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Finally, ValuEngine cut shares of Incyte from a “hold” rating to a “sell” rating in a research report on Wednesday, November 29th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. Incyte presently has an average rating of “Buy” and a consensus price target of $143.25.
COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/08/incyte-incy-scheduled-to-post-earnings-on-thursday.html.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.